Skip to main content
Top
Published in: Molecular Cancer 1/2008

Open Access 01-12-2008 | Short communication

Human ESCs predisposition to karyotypic instability: Is a matter of culture adaptation or differential vulnerability among hESC lines due to inherent properties?

Authors: Puri Catalina, Rosa Montes, Gertru Ligero, Laura Sanchez, Teresa de la Cueva, Clara Bueno, Paola E Leone, Pablo Menendez

Published in: Molecular Cancer | Issue 1/2008

Login to get access

Abstract

Background

The use of human embryonic stem cells (hESCs) in research is increasing and hESCs hold the promise for many biological, clinical and toxicological studies. Human ESCs are expected to be chromosomally stable since karyotypic changes represent a pitfall for potential future applications. Recently, several studies have analysed the genomic stability of several hESC lines maintained after prolonged in vitro culture but controversial data has been reported. Here, we prompted to compare the chromosomal stability of three hESC lines maintained in the same laboratory using identical culture conditions and passaging methods.

Results

Molecular cytogenetic analyses performed in three different hESC lines maintained in parallel in identical culture conditions revealed significant differences among them in regard to their chromosomal integrity. In feeders, the HS181, SHEF-1 and SHEF-3 hESC lines were chromosomally stable up to 185 passages using either mechanical or enzymatic dissection methods. Despite the three hESC lines were maintained under identical conditions, each hESC line behaved differently upon being transferred to a feeder-free culture system. The two younger hESC lines, HS181 (71 passages) and SHEF-3 (51 passages) became chromosomally unstable shortly after being cultured in feeder-free conditions. The HS181 line gained a chromosome 12 by passage 17 and a marker by passage 21, characterized as a gain of chromosome 20 by SKY. Importantly, the mosaicism for trisomy 12 gradually increased up to 89% by passage 30, suggesting that this karyotypic abnormality provides a selective advantage. Similarly, the SHEF-3 line also acquired a trisomy of chromosome 14 as early as passage 10. However, this karyotypic aberration did not confer selective advantage to the genetically abnormal cells within the bulk culture and the level of mosaicism for the trisomy 14 remained overtime between 15%–36%. Strikingly, however, a much older hESC line, SHEF-1, which was maintained for 185 passages in feeders did not undergo any numerical or structural chromosomal change after 30 passages in feeder-free culture and over 215 passages in total.

Conclusion

These results support the concept that feeder-free conditions may partially contribute to hESC chromosomal changes but also confirm the hypothesis that regardless of the culture conditions, culture duration or splitting methods, some hESC lines are inherently more prone than others to karyotypic instability.
Appendix
Available only for authorised users
Literature
1.
go back to reference Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM: Science. 1998, 282: 1145-1147. 10.1126/science.282.5391.1145CrossRefPubMed Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM: Science. 1998, 282: 1145-1147. 10.1126/science.282.5391.1145CrossRefPubMed
2.
go back to reference Bueno C, Montes R, García-Castro J, Greaves M, Menendez P: Drug Discovery Today: Disease Models. 2008, 4: 53-60. 10.1016/j.ddmod.2007.10.004. Bueno C, Montes R, García-Castro J, Greaves M, Menendez P: Drug Discovery Today: Disease Models. 2008, 4: 53-60. 10.1016/j.ddmod.2007.10.004.
3.
go back to reference Draper JS, Smith K, Gokhale P, Moore HD, Maltby E, Johnson J, Meisner L, Zwaka TP, Thomson JA, Andrews PW: Nat Biotech. 2004, 22: 53-54. 10.1038/nbt922.CrossRef Draper JS, Smith K, Gokhale P, Moore HD, Maltby E, Johnson J, Meisner L, Zwaka TP, Thomson JA, Andrews PW: Nat Biotech. 2004, 22: 53-54. 10.1038/nbt922.CrossRef
4.
go back to reference Maitra A, Arking DE, Shivapurkar N, Ikeda M, Stastny V, Kassauei K, Sui G, Cutler DJ, Liu Y, Brimble SN, Noaksson K, Hyllner J, Schulz TC, Zeng X, Freed WJ, Crook J, Abraham S, Colman A, Sartipy P, Matsui S, Carpenter M, Gazdar AF, Rao M, Chakravarti A: Nat Genetics. 2005, 37: 1099-1103. 10.1038/ng1631.CrossRefPubMed Maitra A, Arking DE, Shivapurkar N, Ikeda M, Stastny V, Kassauei K, Sui G, Cutler DJ, Liu Y, Brimble SN, Noaksson K, Hyllner J, Schulz TC, Zeng X, Freed WJ, Crook J, Abraham S, Colman A, Sartipy P, Matsui S, Carpenter M, Gazdar AF, Rao M, Chakravarti A: Nat Genetics. 2005, 37: 1099-1103. 10.1038/ng1631.CrossRefPubMed
5.
go back to reference Imreh MP, Gertow K, Cedervall J, Unger C, Holmberg K, Szöke K, Csöregh L, Fried G, Dilber S, Blennow E, Ahrlund-Richter L: J Cell Biochem. 2006, 99: 508-516. 10.1002/jcb.20897CrossRefPubMed Imreh MP, Gertow K, Cedervall J, Unger C, Holmberg K, Szöke K, Csöregh L, Fried G, Dilber S, Blennow E, Ahrlund-Richter L: J Cell Biochem. 2006, 99: 508-516. 10.1002/jcb.20897CrossRefPubMed
6.
go back to reference Gertow K, Cedervall J, Unger C, Szöke K, Blennow E, Imreh MP, Ahrlund-Richter L: J Cell Biochem. 2007, 100: 1518-1525. 10.1002/jcb.21144CrossRefPubMed Gertow K, Cedervall J, Unger C, Szöke K, Blennow E, Imreh MP, Ahrlund-Richter L: J Cell Biochem. 2007, 100: 1518-1525. 10.1002/jcb.21144CrossRefPubMed
7.
8.
go back to reference Inzunza J, Sahlen S, Holmberg K, Strömberg AM, Teerijoki H, Blennow E, Hovatta O, Malmgren H: Mol Hum Reprod. 2004, 10: 461-466. 10.1093/molehr/gah051CrossRefPubMed Inzunza J, Sahlen S, Holmberg K, Strömberg AM, Teerijoki H, Blennow E, Hovatta O, Malmgren H: Mol Hum Reprod. 2004, 10: 461-466. 10.1093/molehr/gah051CrossRefPubMed
9.
go back to reference Buzzard JJ, Gough NM, Crook JM, Colman A: Nat Biotech. 2004, 22: 381-382. 10.1038/nbt0404-381.1CrossRef Buzzard JJ, Gough NM, Crook JM, Colman A: Nat Biotech. 2004, 22: 381-382. 10.1038/nbt0404-381.1CrossRef
10.
go back to reference Mitalipova M, Rao RR, Hoyer DM, Johnson JA, Meisner LF, Jones KL, Dalton S, Stice SL: Nat Biotech. 2005, 23: 19-20. 10.1038/nbt0105-19.CrossRef Mitalipova M, Rao RR, Hoyer DM, Johnson JA, Meisner LF, Jones KL, Dalton S, Stice SL: Nat Biotech. 2005, 23: 19-20. 10.1038/nbt0105-19.CrossRef
11.
go back to reference Caisander G, Park H, Frej K, Lindqvist J, Bergh C, Lundin K, Hanson C: Chromosome Res. 2006, 14: 131-137. 10.1007/s10577-006-1019-8CrossRefPubMed Caisander G, Park H, Frej K, Lindqvist J, Bergh C, Lundin K, Hanson C: Chromosome Res. 2006, 14: 131-137. 10.1007/s10577-006-1019-8CrossRefPubMed
12.
go back to reference Hardarson T, Caisander G, Sjogren A, Hanson C, Hamberger L, Lundin K: Hum Reprod. 2003, 18: 399-407. 10.1093/humrep/deg092CrossRefPubMed Hardarson T, Caisander G, Sjogren A, Hanson C, Hamberger L, Lundin K: Hum Reprod. 2003, 18: 399-407. 10.1093/humrep/deg092CrossRefPubMed
15.
go back to reference Inzunza J, Gertow K, Stromberg AM, Matilainen E, Blennow E, Skottman H, Wolbank S, Ahrlund-Richter L, Hovatta O: Stem Cells. 2005, 23: 544-549. 10.1634/stemcells.2004-0201CrossRefPubMed Inzunza J, Gertow K, Stromberg AM, Matilainen E, Blennow E, Skottman H, Wolbank S, Ahrlund-Richter L, Hovatta O: Stem Cells. 2005, 23: 544-549. 10.1634/stemcells.2004-0201CrossRefPubMed
16.
go back to reference Hovatta O, Mikkola M, Gertow K, Strömberg AM, Inzunza J, Hreinsson J, Rozell B, Blennow E, Andäng M, Ahrlund-Richter L: A culture system using human foreskin fibroblasts as feeder cells allows production of human embryonic stem cells. Hum Reprod. 2003, 18 (7): 1404-1409. 10.1093/humrep/deg290CrossRefPubMed Hovatta O, Mikkola M, Gertow K, Strömberg AM, Inzunza J, Hreinsson J, Rozell B, Blennow E, Andäng M, Ahrlund-Richter L: A culture system using human foreskin fibroblasts as feeder cells allows production of human embryonic stem cells. Hum Reprod. 2003, 18 (7): 1404-1409. 10.1093/humrep/deg290CrossRefPubMed
17.
go back to reference Menendez P, Wang L, Chadwick K, Li L, Bhatia M: Retroviral transduction of hematopoietic cells differentiated from human embryonic stem cell-derived CD45(neg)PFV hemogenic precursors. Mol Ther. 2004, 10: 1109-1120. 10.1016/j.ymthe.2004.08.016CrossRefPubMed Menendez P, Wang L, Chadwick K, Li L, Bhatia M: Retroviral transduction of hematopoietic cells differentiated from human embryonic stem cell-derived CD45(neg)PFV hemogenic precursors. Mol Ther. 2004, 10: 1109-1120. 10.1016/j.ymthe.2004.08.016CrossRefPubMed
18.
go back to reference Catalina P, Cobo F, Cortes J, Nieto A, Cabrera C, Montes R, Concha A, Menendez P: Conventional and molecular cytogenetic diagnostic methods in stem cell research: a concise review. Cell Biol Int. 2007, 31: 861-869. 10.1016/j.cellbi.2007.03.012CrossRefPubMed Catalina P, Cobo F, Cortes J, Nieto A, Cabrera C, Montes R, Concha A, Menendez P: Conventional and molecular cytogenetic diagnostic methods in stem cell research: a concise review. Cell Biol Int. 2007, 31: 861-869. 10.1016/j.cellbi.2007.03.012CrossRefPubMed
19.
go back to reference Menendez P, Wang L, Bhatia M: Genetic manipulation of human embryonic stem cells: a system to study early human development and potential therapeutic applications. Curr Gene Ther. 2005, 5: 375-385. 10.2174/1566523054546198CrossRefPubMed Menendez P, Wang L, Bhatia M: Genetic manipulation of human embryonic stem cells: a system to study early human development and potential therapeutic applications. Curr Gene Ther. 2005, 5: 375-385. 10.2174/1566523054546198CrossRefPubMed
20.
go back to reference Catalina P, Montes R, Nieto A, Ligero G, Sanchez L, Jara M, Rasillo A, Orfao A, Cigudosa J, Hovatta A, Greaves M, Menendez P: Scientific and clinical opportunity for modeling infant/childhood leukemia using genetically stable human embryonic stem cells. Leuk Res. 2008, doi:10.1016/j.leukres.2008.08.028. Catalina P, Montes R, Nieto A, Ligero G, Sanchez L, Jara M, Rasillo A, Orfao A, Cigudosa J, Hovatta A, Greaves M, Menendez P: Scientific and clinical opportunity for modeling infant/childhood leukemia using genetically stable human embryonic stem cells. Leuk Res. 2008, doi:10.1016/j.leukres.2008.08.028.
21.
go back to reference Gale RE, Hills R, Kottaridis P, Srirangan S, Wheatley K, Burnett AK, Linch DC: No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood. 2005, 106: 3658-3665. 10.1182/blood-2005-03-1323CrossRefPubMed Gale RE, Hills R, Kottaridis P, Srirangan S, Wheatley K, Burnett AK, Linch DC: No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood. 2005, 106: 3658-3665. 10.1182/blood-2005-03-1323CrossRefPubMed
22.
go back to reference Menendez P, Bueno C, Wang L: Human embryonic stem cells: A journey beyond cell replacement therapies. Cytotherapy. 2006, 8: 530-541. 10.1080/14653240601026654CrossRefPubMed Menendez P, Bueno C, Wang L: Human embryonic stem cells: A journey beyond cell replacement therapies. Cytotherapy. 2006, 8: 530-541. 10.1080/14653240601026654CrossRefPubMed
Metadata
Title
Human ESCs predisposition to karyotypic instability: Is a matter of culture adaptation or differential vulnerability among hESC lines due to inherent properties?
Authors
Puri Catalina
Rosa Montes
Gertru Ligero
Laura Sanchez
Teresa de la Cueva
Clara Bueno
Paola E Leone
Pablo Menendez
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2008
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-7-76

Other articles of this Issue 1/2008

Molecular Cancer 1/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine